A Pharmacovigilance Analysis of Ocular Adverse Events Associated with GLP-1 Receptor Agonists - PubMed
7 hours ago
- #pharmacovigilance
- #GLP-1 receptor agonists
- #ocular adverse events
- GLP-1 receptor agonists (GLP-1 RAs) are widely used for type 2 diabetes and obesity, raising concerns about ocular adverse events.
- This study analyzed FDA Adverse Event Reporting System (FAERS) data (2005-2024) for exenatide, tirzepatide, dulaglutide, liraglutide, and semaglutide.
- Ocular adverse events accounted for 3.61% of all GLP-1 RA reports, with a median age of 63 years and 62.6% involving female patients.
- Exenatide had the highest proportion of ocular AEs (33.61%) but showed a significant annual decline in reporting.
- Semaglutide (31.37%) and tirzepatide (12.19%) demonstrated significant year-over-year increases in proportional reporting.
- Semaglutide showed a modestly elevated reporting odds ratio (ROR) of 1.46 for ocular AEs, suggesting a potential safety signal.
- The most common ocular events reported were visual impairment, vision blurred, cataract, and blindness.
- Findings are hypothesis-generating due to limitations like lack of exposure denominators and reporting bias; further research is needed.
- Clinicians are advised to remain vigilant and consider eye care referrals for patients on GLP-1 RAs.